Theragenics lays off workers, restructures development programs

Theragenics plans to lay off 23 workers as it concentrates on its core cancer products and its newly acquired CP Medical, which makes medical devices. Theragenics will discontinue programs for macular degeneration, breast cancer and more. The company says it is looking to its business operations that have the best potential for generating revenue.

- read this AP story for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.